Peptide receptor radioligand therapy (PRRT) is a type of molecular targeted radiation therapy used to treat certain types of cancer. It involves administering a radioactive substance called a radioligand, which binds to specific receptors on cancer cells and delivers targeted radiation to kill those cells.
The process begins by identifying cancers that have an abundance of certain receptors on their cell surfaces, such as somatostatin receptors or glucagon-like peptide-1 (GLP-1) receptors. These receptors can be detected using molecular imaging techniques like PET scans. Radioligands are then developed that specifically bind to those receptors.
Some common radioligands used in PRRT include:
- DOTATATE - binds to somatostatin receptors
- DOTATOC - binds to somatostatin receptors
- GLP-1 analogues - bind to GLP-1 receptors
These radioligands are chemically linked to a radioactive isotope, usually
Lutetium-177 or
Yttrium-90. When injected into the patient's bloodstream, the radioligands circulate and selectively bind to receptors on cancer cells. This allows targeted delivery of radiation to tumors while mostly sparing healthy tissues.
The localized radiation kills cancer cells by damaging their DNA. The radioactivity breaks chemical bonds within cancer cell molecules, interfering with critical cell functions and causing cell death. However, the short-range beta radiation from Lutetium-177 and Yttrium-90 travels just a few millimeters, minimizing exposure of nearby healthy cells.
PRRT can be used to treat:
- Neuroendocrine tumors (NETs), such as of the GI tract, lung, and pancreas
- Pheochromocytomas and paragangliomas
- Meningiomas and other neuroendocrine cancers
The procedure involves outpatient intravenous injections, typically spaced 6-12 weeks apart to allow radiotracer elimination between doses. Patients receive amino acid solutions before and after to protect their kidneys from any radioactivity exposure.
Key advantages of PRRT include:
- Targeted - preferentially kills cancer cells while reducing effects on most healthy tissues
- Systemic - can reach tumors throughout the body via bloodstream
- Low toxicity - generally mild side effects compared to traditional chemotherapy
- Outpatient - does not require hospital admission
At
Vitality Hormone Center, our experienced physicians utilize advanced diagnostics and precision nuclear medicine therapies, including PRRT, to provide comprehensive cancer care. We personalize cutting-edge treatments to achieve the best possible outcomes for every patient. To learn more or schedule a consultation at our state-of-the-art facility, visit
today!
